BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35412579)

  • 1. Large US Study Examines First 6 Months of COVID-19 Vaccine Safety Data.
    Abbasi J
    JAMA; 2022 Apr; 327(14):1323. PubMed ID: 35412579
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
    Schulze-Koops H; Specker C; Skapenko A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33627439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.
    Gundavda MK; Gundavda KK
    Curr Treat Options Oncol; 2021 Sep; 22(10):95. PubMed ID: 34515857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
    Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
    Boyarsky BJ; Ou MT; Greenberg RS; Teles AT; Werbel WA; Avery RK; Massie AB; Segev DL; Garonzik-Wang JM
    Transplantation; 2021 May; 105(5):e56-e57. PubMed ID: 33560728
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccine safety - is the SARS-CoV-2 vaccine any different?
    Tau N; Yahav D; Shepshelovich D
    Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocarditis After BNT162b2 and mRNA-1273 Vaccination.
    Larson KF; Ammirati E; Adler ED; Cooper LT; Hong KN; Saponara G; Couri D; Cereda A; Procopio A; Cavalotti C; Oliva F; Sanna T; Ciconte VA; Onyango G; Holmes DR; Borgeson DD
    Circulation; 2021 Aug; 144(6):506-508. PubMed ID: 34133884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparing for COVID-19 vaccine safety surveillance: A United States perspective.
    Haynes K
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1529-1531. PubMed ID: 32978861
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiac Complications More Common After COVID-19 Than Vaccination.
    Kuehn BM
    JAMA; 2022 May; 327(20):1951. PubMed ID: 35608572
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of mRNA-Based Vaccines for SARS CoV-2.
    Barda B; Cerny A
    Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate reactions after mRNA SARS-CoV-2 vaccination.
    Jeimy S; Wong T; Song C
    CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells.
    Mahroum N; Shoenfeld Y
    Int J Rheum Dis; 2022 Jan; 25(1):5-6. PubMed ID: 34978156
    [No Abstract]   [Full Text] [Related]  

  • 14. The pathogenesis of potential myocarditis induced by COVID-19 vaccine.
    Kounis NG; Koniari I; Mplani V; Velissaris D; Tsigkas G
    Am J Emerg Med; 2022 Jun; 56():382-383. PubMed ID: 34799207
    [No Abstract]   [Full Text] [Related]  

  • 15. Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination.
    Jain E; Donowitz JR; Aarons E; Marshall BC; Miller MP
    Emerg Infect Dis; 2022 May; 28(5):990-993. PubMed ID: 35275051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.
    König M; Torgauten HM; Tran TT; Holmøy T; Vaage JT; Lund-Johansen F; Nygaard GO
    JAMA Neurol; 2022 Mar; 79(3):307-309. PubMed ID: 35072702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covid-19: US Catholics split after bishops' conference recommends against Johnson and Johnson vaccine.
    Dyer O
    BMJ; 2021 Mar; 372():n666. PubMed ID: 33687968
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal COVID-19 Vaccine Safe for Infants.
    Slomski A
    JAMA; 2022 Apr; 327(13):1218. PubMed ID: 35380595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.